VP, Clinical Development at Novavax
Dr. Shinde is vice president of clinical development with the responsibility of leading the clinical development programs for RSV F and seasonal influenza vaccines for older adults. He is a research physician and biotech executive with specialty training in internal medicine, preventive medicine, global health, clinical research, and epidemiology from UCSF, Johns Hopkins, NYU, and the US Centers for Disease Control. He has a decade and a half of combined research and global health experience in seasonal influenza, respiratory syncytial virus (RVS), and viral respiratory disease research, including vaccine clinical development (leading mid- and late-stage vaccine development programs), vaccine pharmacoepidemiology (leading large post-marketing safety and effectiveness trials), real-world evidence generation, and disease epidemiology. Prior to joining Novavax in August 2015, he held various scientific and strategic leadership positions through key roles in public and private sector organizations at the local, national, and international levels, including the US CDC, the New York City Department of Health, the WHO headquarters in Geneva, and GlaxoSmithKline Vaccines. Dr. Shinde received a bachelor of science degree in biochemistry and molecular biology from University of California, San Diego, a master of public health degree in epidemiology and international public health from Johns Hopkins University, and a doctor of medicine degree from University of California, San Francisco.